Duenzinger, Ulrich

Boehringer Ingelheim (Germany)

1 paper on CoChat

Most cited papers

Verified
Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan.
Hofmann, M. H., Lu, H., Duenzinger, U., Gerlach, D., Trapani, F., Machado, A. A., Daniele, J. R., Waizenegger, I., Gmachl, M., Rudolph, D., et al. (2021) · Cancer Research
Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways
Cited by 20

Go further with a free account

Verify every reference, keep papers in a library, and ask questions across them.

Sign up - it is free